SCHEMBL6165563

SCHEMBL6165563

COc1ccc(C)cc1Nc1nc2ccc(CC(=O)CNc3ccc(C(C)CC(=O)O)nc3)cc2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
POLB P06746 1/20 0.35
PPARG P37231 1/20 0.35
KMT2A Q03164 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
ITGA4 P13612 8/20 0.35
ITGB1 P05556 2/20 0.33
INSR P06213 1/20 0.33
ALK Q9UM73 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6163435 0.92 ITGA4 (0.38) MAPTTP53ITGA4ITGB1INSR
SCHEMBL6163004 0.91 MAPT (0.43) MAPTTP53ALDH1A1GAARXFP1
SCHEMBL6164422 0.86 TP53 (0.39) MAPTTP53GAARXFP1ITGA4
SCHEMBL6165568 0.85 MAPT (0.38) MAPTTP53ALDH1A1GAARXFP1
SCHEMBL6167394 0.84 MAPT (0.42) MAPTGAAMEN1POLBKMT2A
SCHEMBL6163937 0.84 ITGA4 (0.41) MAPTTP53POLBPPARGITGA4
SCHEMBL6165940 0.84 NPC1 (0.40) MAPTALDH1A1ITGA4ITGB1RAB9A
SCHEMBL6164188 0.84 ITGA4 (0.39) MAPTTP53POLBITGA4ITGB1
SCHEMBL6162941 0.83 ITGA4 (0.38) MAPTTP53ITGA4ITGB1
SCHEMBL6164584 0.82 ITGA4 (0.46) MAPTTP53ALDH1A1RXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183254-B1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LTD (GB) 2005-01-12 EP disclosed
US-6706738-B2 ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS AVENTIS PHARMA LIMITED (GB) 2004-03-16 US disclosed
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists AVENTIS PHARMA LIMITED (GB) 2002-11-21 US disclosed
EP-1183254-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS Aventis Pharma Limited (GB) 2002-03-06 EP disclosed
WO-2000061580-A1 SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS INTEGRIN ANTAGONISTS AVENTIS PHARMA LIMITED (GB) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173506-A1 Substituted bicyclic heteroaryl compounds and their use as integrin antagonists VCAM1, ITGA4, ITGA1 MAPT 4812/4885TP53 3768/4885ALDH1A1 667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.